Montag & Associates
KYMR icon

Montag & Associates’s Kymera Therapeutics KYMR Stock Holding History

Montag & Associates’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-6
Closed -$340 – 1066
2025
Q3 		$340 Buy
+6
New +$271 ﹤0.01% 1104

Other funds holding KYMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Avoro Capital Advisors
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BVF Inc
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Montag & Associates's KYMR Position: Q4 2025 in Review

Montag & Associates sold out of Kymera Therapeutics (KYMR) in Q4 2025, closing a stake of 6 shares — an estimated $340 sold.

Montag & Associates first reported a position in KYMR in Q3 2025 and held it in 1 quarter. The position peaked at $340 in Q3 2025. 254 funds tracked by Wall St. Rank hold KYMR as of Q4 2025.

  • Montag & Associates reported no remaining Kymera Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Montag & Associates sold 6 Kymera Therapeutics shares in Q4 2025, an estimated $340.
  • Montag & Associates first reported a position in Kymera Therapeutics in Q3 2025 and held it in 1 quarter.
  • Montag & Associates's Kymera Therapeutics position peaked at $340 in Q3 2025.
  • 254 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q4 2025.

Based on Montag & Associates's 13F filing for Q4 2025, filed 2 Feb 2026.